4.5 Review

How synthetic biology can help bioremediation

Journal

CURRENT OPINION IN CHEMICAL BIOLOGY
Volume 58, Issue -, Pages 86-95

Publisher

ELSEVIER SCI LTD
DOI: 10.1016/j.cbpa.2020.07.004

Keywords

Bioremediation; Xenobiotics; Synthetic biology; Heavy metals; Organic pollutants

Funding

  1. Biotechnology and Biological Sciences Research Council (BBSRC)
  2. UK Ministry of Defence
  3. Strategic Environmental Research and Development Program (SERDP) of the US Department of Defense
  4. Environmental Security Technology Certification Program (ESTCP) of the US Department of Defense

Ask authors/readers for more resources

The World Health Organization reported that an estimated 12.6 million people died as a result of living or working in an unhealthy environment in 2012, nearly 1 in 4 of total global deaths. Air, water and soil pollution were the significant risk factors, and there is an urgent need for effective remediation strategies. But tackling this problem is not easy; there are many different types of pollutants, often widely dispersed, difficult to locate and identify, and in many cases cost-effective clean-up techniques are lacking. Biology offers enormous potential as a tool to develop microbial and plant-based solutions to remediate and restore our environment. Advances in synthetic biology are unlocking this potential enabling the design of tailor-made organisms for bioremediation. In this article, we showcase examples of xenobiotic clean-up to illustrate current achievements and discuss the limitations to advancing this promising technology to make real-world improvements in the remediation of global pollution.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.5
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

Article Medicine, Research & Experimental

Mixed Reality Enhanced Otolaryngology Case-Based Learning: A Randomized Educational Study

Rukhnoor Malik, Jonathan R. Abbas, Ceyon Jayarajah, Iain A. Bruce, Neil Tolley

Summary: This study investigated the value of enhancing traditional remote case-based teaching with the HoloLens2. The results showed that HoloLens2 enhanced teaching could improve student performance and increase student engagement and question asking compared to conventional remote teaching. Students were satisfied with the teaching using HoloLens2 and believed it helped concept demonstration and student engagement.

LARYNGOSCOPE (2023)

Article Rheumatology

Sustained glucocorticoid tapering in the phase 3 trials of anifrolumab: a post hoc analysis of the TULIP-1 and TULIP-2 trials

Ian N. Bruce, Ronald F. van Vollenhoven, Eric F. Morand, Richard A. Furie, Susan Manzi, William B. White, Gabriel Abreu, Raj Tummala

Summary: This study evaluated the effects of sustained glucocorticoid tapering in patients with SLE. The results showed that sustained glucocorticoid tapering is associated with reduced glucocorticoid dosage, improved patient-reported outcomes, and fewer adverse events. Treatment with anifrolumab has the potential to reduce disease activity and glucocorticoid exposure.

RHEUMATOLOGY (2023)

Article Economics

Valuing Health Gain from Composite Response Endpoints for Multisystem Diseases

Sean P. Gavan, Ian N. Bruce, Katherine Payne

Summary: This study aimed to estimate the value of health gain for patients with a multisystem disease using specific composite response endpoints. Data from a national register were used to compare health utility values and quality-adjusted life-years for responders and nonresponders. The study found that bespoke composite response endpoints can be used to assess treatment response for multisystem diseases and provide valuable evidence for health technology assessment, decision making, and economic evaluation.

VALUE IN HEALTH (2023)

Article Radiology, Nuclear Medicine & Medical Imaging

Imaging biomarkers of lung ventilation in interstitial lung disease from 129Xe and oxygen enhanced 1H MRI

Marta Tibiletti, James A. Eaden, Josephine H. Naish, Paul J. C. Hughes, John C. Waterton, Matthew J. Heaton, Nazia Chaudhuri, Sarah Skeoch, Ian N. Bruce, Stephen Bianchi, Jim M. Wild, Geoff J. M. Parker

Summary: This study aimed to compare imaging biomarkers from hyperpolarised 129Xe ventilation MRI and dynamic oxygen-enhanced MRI (OE-MRI) with standard pulmonary function tests (PFT) in interstitial lung disease (ILD) patients. The results showed that the ventilation biomarkers were not able to differentiate between ILD subtypes and had limited correlation with PFT changes.

MAGNETIC RESONANCE IMAGING (2023)

Article Rheumatology

Determinants of health-related quality of life across the spectrum of connective tissue diseases using latent profile analysis: results from the LEAP cohort

Sarah Dyball, John A. Reynolds, Ariane L. Herrick, Sahena Haque, Hector Chinoy, Ellen Bruce, Sophia Naz, Ben Parker, Ian N. Bruce

Summary: This study aimed to determine different subgroups of patients with CTD and their associated patient-level characteristics related to health-related quality of life (HRQoL). The results showed the existence of different HRQoL patterns and these subgroups were not primarily driven by specific diagnoses or autoantibody profiles. Black background, Indo-Asian background, concomitant fibromyalgia, sicca symptoms, and multimorbidity were associated with poor HRQoL.

RHEUMATOLOGY (2023)

Article Rheumatology

Assessing the Costs of Neuropsychiatric Disease in the Systemic Lupus International Collaborating Clinics Cohort Using Multistate Modeling

Ann E. Clarke, John G. Hanly, Murray B. Urowitz, Yvan St. Pierre, Caroline Gordon, Sang-Cheol Bae, Juanita Romero-Diaz, Jorge Sanchez-Guerrero, Sasha Bernatsky, Daniel J. Wallace, David A. Isenberg, Anisur Rahman, Joan T. Merrill, Paul R. Fortin, Dafna D. Gladman, Ian N. Bruce, Michelle Petri, Ellen M. Ginzler, Mary Anne Dooley, Rosalind Ramsey-Goldman, Susan Manzi, Andreas Jonsen, Graciela S. Alarcon, Ronald F. Van Vollenhoven, Cynthia Aranow, Meggan Mackay, Guillermo Ruiz-Irastorza, S. Sam Lim, Murat Inanc, Kenneth C. Kalunian, Soren Jacobsen, Christine A. Peschken, Diane L. Kamen, Anca Askanase, Vernon Farewell

Summary: The objective of this study was to estimate the costs associated with neuropsychiatric events in SLE. The study found that new/ongoing SLE or non-SLE NP events incurred higher direct and indirect costs. Indirect costs exceeded direct costs by 3.0 to 5.2 fold.

ARTHRITIS CARE & RESEARCH (2023)

Article Rheumatology

Machine learning identifies clusters of longitudinal autoantibody profiles predictive of systemic lupus erythematosus disease outcomes

May Yee Choi, Irene Chen, Ann Elaine Clarke, Marvin J. Fritzler, Katherine A. Buhler, Murray Urowitz, John Hanly, Yvan St-Pierre, Caroline Gordon, Sang-Cheol Bae, Juanita Romero-Diaz, Jorge Sanchez-Guerrero, Sasha Bernatsky, Daniel J. Wallace, David Alan Isenberg, Anisur Rahman, Joan T. Merrill, Paul R. Fortin, Dafna D. Gladman, Ian N. Bruce, Michelle Petri, Ellen M. Ginzler, Mary Anne Dooley, Rosalind Ramsey-Goldman, Susan Manzi, Andreas Jonsen, Graciela S. Alarcon, Ronald F. van Vollenhoven, Cynthia Aranow, Meggan Mackay, Guillermo Ruiz-Irastorza, Sam Lim, Murat Inanc, Kenneth Kalunian, Soren Jacobsen, Christine Peschken, Diane L. Kamen, Anca Askanase, Jill P. Buyon, David Sontag, Karen H. Costenbader

Summary: A novel longitudinal clustering technique was used to analyze comprehensive autoantibody data from a large, well-characterised, multinational inception SLE cohort, in order to determine predictive profiles of clinical outcomes.

ANNALS OF THE RHEUMATIC DISEASES (2023)

Article Medicine, General & Internal

Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II)

Michelle Petri, Ian N. Bruce, Thomas Doerner, Yoshiya Tanaka, Eric F. Morand, Kenneth C. Kalunian, Mario H. Cardiel, Maria E. Silk, Christina L. Dickson, Gabriella Meszaros, Lu Zhang, Bochao Jia, Youna Zhao, Conor J. McVeigh, Marta Mosca

Summary: Baricitinib, an oral inhibitor of Janus kinase 1 and 2, was evaluated as a treatment for patients with systemic lupus erythematosus (SLE) in a 52-week phase 3 study. The study found that baricitinib did not significantly improve SLE disease activity compared with placebo, and there were no new safety concerns.

LANCET (2023)

Article Rheumatology

In-person versus virtual administration of the American College of Radiology gold standard cognitive battery in systemic lupus erythematosus: Are they interchangeable?

M. L. Barraclough, J. P. Diaz-Martinez, A. Knight, K. Bingham, J. Su, M. Kakvan, C. Munoz Grajales, M. C. Tartaglia, L. Ruttan, J. Wither, M. Y. Choi, D. Bonilla, N. Anderson, S. Appenzeller, B. Parker, P. Katz, D. Beaton, R. Green, I. N. Bruce, Z. Touma

Summary: During the COVID-19 pandemic, our longitudinal study on cognitive impairment in systemic lupus erythematosus (SLE) had to adapt and switch from in-person to virtual administration. We found that the method of administration had an impact on cognitive performance and classification. Approximately 42% of the tests in the battery encountered issues when moved from in-person to virtual administration, highlighting the need for caution when comparing results.

LUPUS (2023)

Article Medicine, General & Internal

Listening effort and downstream effects due to hearing loss in children and young people: an online quantitative questionnaire-based observational study

Callum Andrew Shields, Mark Sladen, Azita Rajai, Hannah Guest, Iain Bruce, Karolina Kluk, Jaya Nichani

Summary: This study aims to explore the use of existing questionnaire-based outcome instruments to evaluate listening effort (LE) and its associated consequences in children and young people with and without hearing loss. Participants will complete online questionnaires and a hearing test, and the data will be analyzed to identify correlations between LE and other outcomes.

BMJ OPEN (2023)

Article Medicine, General & Internal

A successful antenatal outcome in a patient with refractory Takayasu's arteritis treated with tocilizumab throughout pregnancy-a case report

Behram Khan, Trixy David, Jon Sussman, Louise Simcox, Clare Tower, Calvin Soh, Ian N. Bruce

Summary: This case report describes a patient with extensive Takayasu's arteritis who was treated with TCZ during pregnancy. The patient was closely monitored and TCZ was continued due to the perceived benefits outweighing the risks. The case also highlights the importance of accurate blood pressure monitoring in patients with extensive disease. The patient's disease remained stable throughout pregnancy and postpartum, with a successful outcome and no maternal or fetal complications.

OXFORD MEDICAL CASE REPORTS (2023)

Review Otorhinolaryngology

Mobile audiometry for hearing threshold assessment: A systematic review and meta-analysis

Babatunde Oremule, Jonathan Abbas, Gabrielle Saunders, Karolina Kluk, Rachel Isba, Sebastian Bate, Iain Bruce

Summary: This systematic review examined the options available for mobile audiometry (MA), assessed their accuracy in measuring hearing thresholds, and explored factors that might influence their accuracy. The findings suggest that MA compares favorably to conventional audiometry (CA) in measuring hearing thresholds and has a role in providing access to hearing assessment in situations where CA is not available or feasible.

CLINICAL OTOLARYNGOLOGY (2023)

Article Rheumatology

Early infection risk in patients with systemic lupus erythematosus treated with rituximab or belimumab from the British Isles Lupus Assessment Group Biologics Register (BILAG-BR): a prospective longitudinal study

Mia Rodziewicz, Sarah Dyball, Mark Lunt, Stephen McDonald, Emily Sutton, Ben Parker, Ian N. Bruce

Summary: This study investigated the frequency and risk factors for serious infections in patients with moderate-to-severe systemic lupus erythematosus (SLE) treated with rituximab, belimumab, and standard therapies. The study found that rituximab, belimumab, and standard therapy had similar risks for serious infections. Key risk factors for serious infections included multimorbidity, hypogammaglobulinemia, and increased glucocorticoid doses. These findings are important for guiding the treatment and management of SLE patients.

LANCET RHEUMATOLOGY (2023)

Article Rheumatology

Lupus spectrum ambiguity has long-term negative implications for patients

Ian N. Bruce, Joy Buie, Lauren Bloch, Sang-Cheol Bae, Karen Costenbader, Roger A. Levy, Victoria P. Werth, Ashley Marion, Sanjyot Sangodkar, Susan Manzi

Summary: Lupus, a complex disease, poses challenges in diagnosis due to non-specific symptoms and a lack of diagnostic criteria and referral pathways. To address these issues, virtual meetings were held with experts in lupus care, including physicians, treatment developers, and patient advocacy group representatives. The discussions highlighted the need for a clearer understanding of lupus, advancements in biotechnology, and potential development of a lupus spectrum to support timely and accurate diagnosis.

LUPUS SCIENCE & MEDICINE (2023)

Letter Health Care Sciences & Services

Letter in reply: indirect treatment comparison of anifrolumab efficacy versus belimumab in adults with systemic lupus erythematosus

Ian N. Bruce, Sarowar Golam, Jason Steenkamp, Pearl Wang, Evelyn Worthington, Barnabas Desta, Konstantina Psachoulia, Wilma Erhardt, Raj Tummala

JOURNAL OF COMPARATIVE EFFECTIVENESS RESEARCH (2023)

No Data Available